Manufacturing, Biologic Drugs

Chime Biologics Forms mAb Development and Manufacturing Deal with Leads Biolabs and BeiGene

July 06, 2023

Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.

Syngene Adds Biologics Drug Substance Manufacturing Capacity with Facility Acquisition

July 06, 2023

Syngene has acquired a multi-modal biologics drug substance manufacturing facility in Bangalore, India, from Stelis Biopharma.

Frontrunner in Therapies for Complement-Mediated Diseases

July 02, 2023

A novel complement therapeutic CTx001 offers a novel approach to treating geographic atrophy.

Enzene Biosciences Invests $50 Million into New Jersey Biomanufacturing Facility

June 21, 2023

India’s Enzene Biosciences is investing $50 Million into a new biopharma manufacturing plant in Hopewell, NJ.

Mendus and NorthXBiologics Enter Cell Therapy Manufacturing Alliance

June 15, 2023

Mendus and NorthX Biologics will work to develop and commercialize Mendus’ lead asset, vididencel, an allogeneic dendritic cell vaccine.

Charles River Laboratories Launches LVV Packaging Plasmids

June 15, 2023

Charles River’s off-the-shelf lentiviral vector packaging plasmids are intended for use with cell and gene therapies.

WuXi Biologics Expands Manufacturing Capacity in Germany

June 01, 2023

WuXi Biologics is expanding its manufacturing capacity for drug substance and drug product at its sites in Leverkusen and Wuppertal, Germany.

Aseptic Processes Safeguard Biologics

May 15, 2023

Aseptic techniques must be practiced throughout all stages of biologics production.

Optimizing the Manufacture of Emerging Therapies

May 02, 2023

Guidance for GMP manufacture of emerging therapies has evolved to accommodate innovation and the broader spectrum of products in development, but greater harmonization is still needed.

Avid Bioservices Expands Mammalian Cell Capacity

April 14, 2023

Avid Bioservices has launched new CGMP mammalian cell manufacturing suites at its Myford, Calif., facility.